Several hedge funds have recently adjusted their investments in Becton, Dickinson and Company (BDX). Jennison Associates LLC increased their stake by 4.9%, acquiring 18,786 additional shares. Norden Group LLC notably raised their stake by 2,086.7%, adding 49,559 shares. Franklin Street Advisors bought new shares worth about $12 million, while Avity Investment Management increased theirs by 3.5%. Caden Capital Partners boosted their stake by 26.7% last quarter. Overall, 86.97% of BDX shares are held by institutional investors.
Analyst Ratings
Recent analyses have shown positive movements for BDX shares. Evercore ISI raised its price target from $286 to $290, rating the stock as “outperform.” Other analysts, including StockNews.com and Citigroup, improved their ratings and targets, positioning the average target at $282.63 with a consensus rating of “Buy.”
Price and Earnings Performance
As of Thursday, BDX shares opened at $239.76, with a market cap of $69.29 billion. The company reported earnings of $3.50 per share for the last quarter, exceeding expectations. Revenue was $4.99 billion, a 2.3% increase from the previous year. Analysts project an EPS of 13.1 for the current year.
Dividend Announcement
The company declared a quarterly dividend of $0.95 per share, payable on September 30th. This results in an annualized dividend of $3.80, with a yield of 1.58%.
Company Overview
Becton, Dickinson and Company develops medical supplies and devices across three segments: BD Medical, BD Life Sciences, and BD Interventional.
Learn More
- Five stocks we like better than Becton, Dickinson and Company
- What is the Shanghai Stock Exchange Composite Index?
- S&P 500 Hitting Resistance: Best Upside Stocks
- Natural Gas Prices Rally: Beneficial Stocks
- Nikes Post-Earnings Drop: Buying Opportunity
- Russell 2000 Index for Profitable Trading
- Microsofts Targeted Upside
Receive Daily News & Ratings for Becton Dickinson – Enter your email below for daily summaries from MarketBeat.
`
